GSK690693, an Akt inhibitor currently in phase I clinical trials, was reported to inhibit cancer cell proliferation and induce apoptosis in a subset of tumor cells with potency consistent with the intracellular inhibition of Akt kinase activity [45]. This evidence concerns the gene AKT1 and neoplasm.